Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Net margin
Solventum Corporation's net margin over the twelve months to 30 June 2026 was 17.3%, down 1.4 percentage points from fiscal 2025 (18.7%). That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 18.7% | 12.89 |
| FY2024 | 5.80% | (10.62) |
| FY2023 | 16.4% | (0.10) |
| FY2022 | 16.5% | — |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 4.16% | 3.51 |
| Mar 2026 | 0.65% | (2.50) |
| Dec 2025 | 3.15% | (57.25) |
| Sep 2025 | 60.4% | 56.24 |
| 10 more quarters | Free account |
Net margin against peers
| Company | Net margin |
|---|---|
| SOLV Solventum Corporation | 17.3% |
| WST West Pharmaceutical Services, Inc. compare | 17.0% |
| COO The Cooper Companies, Inc. compare | 13.5% |
| ALGN Align Technology, Inc. compare | 9.99% |
| ATR AptarGroup, Inc. compare | 9.22% |
| ALC Alcon compare | 5.92% |
| RGEN Repligen Corporation compare | 5.29% |
| AVTR Avantor, Inc. compare | −8.81% |
| BAX Baxter International Inc. compare | −9.27% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement